Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) EBIT (2016 - 2025)

Fortress Biotech (FBIO) has 13 years of EBIT data on record, last reported at -$6.6 million in Q3 2025.

  • For Q3 2025, EBIT rose 69.94% year-over-year to -$6.6 million; the TTM value through Sep 2025 reached -$89.3 million, up 15.84%, while the annual FY2024 figure was -$110.4 million, 22.46% up from the prior year.
  • EBIT reached -$6.6 million in Q3 2025 per FBIO's latest filing, up from -$36.5 million in the prior quarter.
  • Across five years, EBIT topped out at -$6.6 million in Q3 2025 and bottomed at -$62.0 million in Q4 2021.
  • Average EBIT over 5 years is -$37.2 million, with a median of -$36.6 million recorded in 2024.
  • Peak YoY movement for EBIT: tumbled 155.12% in 2021, then surged 72.88% in 2023.
  • A 5-year view of EBIT shows it stood at -$62.0 million in 2021, then increased by 11.88% to -$54.6 million in 2022, then surged by 64.1% to -$19.6 million in 2023, then fell by 21.52% to -$23.8 million in 2024, then skyrocketed by 72.13% to -$6.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT were -$6.6 million in Q3 2025, -$36.5 million in Q2 2025, and -$22.3 million in Q1 2025.